子宫内膜异位症血瘀证差异蛋白质组学研究
|
摘要
研究背景：子宫内膜异位症(Endometriosis,EMT)是育龄妇女的多发病,严重影响女性生殖健康和生活质量。证候是疾病一定阶段病因、病位、病性、病势的综合表现,也是中医药理论研究的核心内容,开展中医“证候”本质研究,揭示证候的科学内涵是中医基础理论现代化进程中的关键环节,而证候生物学基础研究的突破则是证候科学内涵得以阐明的保障。血瘀证是中医临床多种疾病的基本证型,也是子宫内膜异位症的核心证候类型。在前期研究中,曾发现该证型的异位和在位内膜在组织形态学和细胞凋亡相关因子的表达存在差异,为从蛋白组学水平探索EMT的不同证候的特异性标志物的研究工作奠定了基础。对子宫内膜异位症血瘀证进行深入、系统的现代研究,有助于对本病的准确诊断和有效治疗。
目的：①通过蛋白组学技术分离并鉴定EMT血瘀证、气滞血瘀证、肾虚血瘀证患者在位和异位内膜的差异蛋白质,寻找EMT证候特异性蛋白质；②从蛋白质水平探讨EMT血瘀证、气滞血瘀证、肾虚血瘀证的实质,揭示EMT血瘀证辨证的分子生物学基础,建立EMT的蛋白质分子微观辨证和诊断体系,探讨EMT证候的演变规律、证候的辨治靶点,寻找有意义的分子标记物及基因干预的靶点。
方法：取6例EMTI血瘀证、气滞血瘀证、肾虚血瘀证患者增生期在位和异位内膜组织和6例增生期正常子宫内膜组织标本,将各种证型的每两例标本进行随机等量混匀,得到3组标本并提取组织总蛋白。通过双向电泳技术得到3组双向电泳凝胶图谱。检测出的表达差异点经基质辅助激光解吸电离飞行时间质谱(MALDI-TOF-TOF/MS)及蛋白质数据库检索进行蛋白质鉴定。
结果：在3组差异蛋白中进行比较,最终得到三次重复试验所获得的各证型的差异蛋白。其中血瘀证在位内膜差异蛋白2个,异位内膜差异蛋白1个。肾虚血瘀证在位内膜差异蛋白3个,异位内膜差异蛋白3个。气滞血瘀证瘀型在位内膜差异蛋白3个,异位内膜差异蛋白4个。根据各证型差异蛋白比较,可以发现膜联蛋白在肾虚血瘀证在位内膜和异位内膜均有高表达,肌球蛋白轻链3在气滞血瘀证在位内膜和异位内膜均有高表达。
结论：EMT血瘀证、气滞血瘀证、肾虚血瘀证之间蛋白质组成分存在差异,这些差异可能是证候实质的内在根源。这些差异蛋白可能成为EMT不同证候发病的候选生物标志物。
Background:Endometriosis (EMT) is a frequently-occurring disease in women of childbearing age. It imposes a dramatic impact on women reproductive health and quality of life. Syndrome is the comprehensive performance of etiology, location, quality and trend of diseases in a certain phase, and it's the central conception of theoretic research of traditional Chinese Medicine (TCM). Therefore, to investigate the innate character and to reveal the scientific essence of syndromes are the crucial point of modernization of TCM theories. Furthermore, the breakthrough of biological research about syndromes might confirm the clarification of its scientific essence. Blood stasis syndrome is a common pattern in various clinic diseases and is the key pattern in EMT. In previous research, the differences on histological morphology and apoptosis associated factors between ectopic and reigning endometrium were revealed, that applied a foundation for further study on specific markers among EMT syndromes by proteomics. It is predominantly useful for EMT's accurate diagnosis and effective management when the profound and systemic study on syndrome of blood stasis of EMT is accomplished.
Objective:①To separate and identify the global protein by proteomics from EMT ectopic and reigning endometrium in3syndromes including blood stasis syndrome, qi stagnation and blood stasis syndrome as well as kidney deficiency and blood stasis syndrome, and to reveal the specific protein for EMT syndrome.②To detect the innate characters of the three syndromes of EMT, to investigate the molecular biological basis for syndrome differentiation of blood stasis of EMT, to establish the system of microscopic identification and diagnosis for EMT protein, to discover the transmission principles of EMT syndromes and their targets, and to search the meaningful molecular marker and genetic associated targets.
Methods:Tissues from ectopic and reigning endometrium in proliferative phase in EMT patients were extracted, including6of blood stasis syndrome,6of qi stagnation and blood stasis syndrome, as well as6of kidney deficiency and blood stasis syndrome, and6specimens of normal endometrium in proliferative phase were extracted. Then each two specimens in all syndromes were randomly and isometricly mixed, consequently3groups of specimens were achieved to extract the total protein. Finally3groups'spectrums of running gel were accomplished by two-dimensional electrophoresis, and the different points were measured by MALDI-TOF-TOF/MS and protein database.
Results:In blood stasis syndrome, two differential proteins from reigning endomutrium were obtained, while one from ectopic endometrium was obtained. In kidney deficiency and blood stasis syndrome, three differential proteins from reigning endomutrium were obtained, while three from ectopic endometrium were obtained. In qi stagnation and blood stasis syndrome, three differential proteins from reigning endomutrium were obtained, while four from ectopic endometrium were obtained. The annexin was highly expressed in both reigning and ectopic endometrium of kidney deficiency and blood stasis syndrome. The myoglobulin light chain3was highly expressed in both reigning and ectopic endometrium of qi stagnation and blood stasis syndrome.
Conclusion:There are differential protein expressions among EMT three syndromes, which might be the inner origin of syndrome characters, and these differential proteins might be as the candidate biomarkers for pathogenesis of EMT various syndromes.
目的：①通过蛋白组学技术分离并鉴定EMT血瘀证、气滞血瘀证、肾虚血瘀证患者在位和异位内膜的差异蛋白质,寻找EMT证候特异性蛋白质；②从蛋白质水平探讨EMT血瘀证、气滞血瘀证、肾虚血瘀证的实质,揭示EMT血瘀证辨证的分子生物学基础,建立EMT的蛋白质分子微观辨证和诊断体系,探讨EMT证候的演变规律、证候的辨治靶点,寻找有意义的分子标记物及基因干预的靶点。
方法：取6例EMTI血瘀证、气滞血瘀证、肾虚血瘀证患者增生期在位和异位内膜组织和6例增生期正常子宫内膜组织标本,将各种证型的每两例标本进行随机等量混匀,得到3组标本并提取组织总蛋白。通过双向电泳技术得到3组双向电泳凝胶图谱。检测出的表达差异点经基质辅助激光解吸电离飞行时间质谱(MALDI-TOF-TOF/MS)及蛋白质数据库检索进行蛋白质鉴定。
结果：在3组差异蛋白中进行比较,最终得到三次重复试验所获得的各证型的差异蛋白。其中血瘀证在位内膜差异蛋白2个,异位内膜差异蛋白1个。肾虚血瘀证在位内膜差异蛋白3个,异位内膜差异蛋白3个。气滞血瘀证瘀型在位内膜差异蛋白3个,异位内膜差异蛋白4个。根据各证型差异蛋白比较,可以发现膜联蛋白在肾虚血瘀证在位内膜和异位内膜均有高表达,肌球蛋白轻链3在气滞血瘀证在位内膜和异位内膜均有高表达。
结论：EMT血瘀证、气滞血瘀证、肾虚血瘀证之间蛋白质组成分存在差异,这些差异可能是证候实质的内在根源。这些差异蛋白可能成为EMT不同证候发病的候选生物标志物。
Background:Endometriosis (EMT) is a frequently-occurring disease in women of childbearing age. It imposes a dramatic impact on women reproductive health and quality of life. Syndrome is the comprehensive performance of etiology, location, quality and trend of diseases in a certain phase, and it's the central conception of theoretic research of traditional Chinese Medicine (TCM). Therefore, to investigate the innate character and to reveal the scientific essence of syndromes are the crucial point of modernization of TCM theories. Furthermore, the breakthrough of biological research about syndromes might confirm the clarification of its scientific essence. Blood stasis syndrome is a common pattern in various clinic diseases and is the key pattern in EMT. In previous research, the differences on histological morphology and apoptosis associated factors between ectopic and reigning endometrium were revealed, that applied a foundation for further study on specific markers among EMT syndromes by proteomics. It is predominantly useful for EMT's accurate diagnosis and effective management when the profound and systemic study on syndrome of blood stasis of EMT is accomplished.
Objective:①To separate and identify the global protein by proteomics from EMT ectopic and reigning endometrium in3syndromes including blood stasis syndrome, qi stagnation and blood stasis syndrome as well as kidney deficiency and blood stasis syndrome, and to reveal the specific protein for EMT syndrome.②To detect the innate characters of the three syndromes of EMT, to investigate the molecular biological basis for syndrome differentiation of blood stasis of EMT, to establish the system of microscopic identification and diagnosis for EMT protein, to discover the transmission principles of EMT syndromes and their targets, and to search the meaningful molecular marker and genetic associated targets.
Methods:Tissues from ectopic and reigning endometrium in proliferative phase in EMT patients were extracted, including6of blood stasis syndrome,6of qi stagnation and blood stasis syndrome, as well as6of kidney deficiency and blood stasis syndrome, and6specimens of normal endometrium in proliferative phase were extracted. Then each two specimens in all syndromes were randomly and isometricly mixed, consequently3groups of specimens were achieved to extract the total protein. Finally3groups'spectrums of running gel were accomplished by two-dimensional electrophoresis, and the different points were measured by MALDI-TOF-TOF/MS and protein database.
Results:In blood stasis syndrome, two differential proteins from reigning endomutrium were obtained, while one from ectopic endometrium was obtained. In kidney deficiency and blood stasis syndrome, three differential proteins from reigning endomutrium were obtained, while three from ectopic endometrium were obtained. In qi stagnation and blood stasis syndrome, three differential proteins from reigning endomutrium were obtained, while four from ectopic endometrium were obtained. The annexin was highly expressed in both reigning and ectopic endometrium of kidney deficiency and blood stasis syndrome. The myoglobulin light chain3was highly expressed in both reigning and ectopic endometrium of qi stagnation and blood stasis syndrome.
Conclusion:There are differential protein expressions among EMT three syndromes, which might be the inner origin of syndrome characters, and these differential proteins might be as the candidate biomarkers for pathogenesis of EMT various syndromes.
引文
[1]郎景和.子宫内膜异位症研究新理程[J].中华妇产科杂志,2005,40(1)：3-4.
[2]姚瑶珊,陈忠东.子宫内膜异位症发病机制的研究进展[J].中南医学科学杂志,2012,40(4)：413-415.
[3]Wasinger VC,Cordwell SJ,Cerpa-Polja kA,et al.Progress with gene-product mapping of the Mollicutm:Mycoplasma genitalium[J].Electrophoresis,1995,16(7):] 090-1094.
[4]卢德赵,沃兴德.蛋白质组学技术在中医药研究中的应用[J].浙江中西医结合杂志,2007,17(4)：262-264.
[5]朱明丹,杜武勋,姜民.中医证候与基因、蛋白质、代谢组学研究思路探讨[J].中国中医基础医学杂志,2010,16(1)：69-71.
[6]裘吉生主编,珍本医书集成·方书类(甲)[M].上海.上海科学技术出版社,1985：81.
[7]王东梅.“逆经痛”析[J].山东中医药大学学报.2000,(24)3：181-183.
[8]司徒仪主编,子宫内膜异位症中西医结合治疗[M].人民卫生出版社,2006年第1版：4.
[9]曹泽毅,主编.中华妇产科学[M],人民卫生出版社,2008年第二版：1486.
[10]郎景和.子宫内膜异位疟研究新理程[J].中华妇产科杂志，,2005,40(1)：3-4.
[11]郎景和.子宫内膜内膜异位症研究的任务与展望[J].中华妇产科杂志,2006,41(5)：289-290.
[12]宗利丽,李亚里,汪龙霞.子宫内膜异位症猕猴动物模型的建立[J].第一军医大学学报.，2003,，23(10)：1006-1009.
[13]黄燕清,黄峥狲玲,等.腹腔液基质金属蛋白酶-1、-2、-3、-9与子宫内膜异位症的相关性[J].广东医学,2010.31(4)：433-435.
[14]徐蕾,张向宁.内异症患者异位、在位子宫内膜中HGF、MMP-2、MMP-9的表达变化及意义[J].山东医药,2010,50：86-87.
[15]Taylor RN,Yu J.Torees PB,et al.Mechanistic and therapeutic implications of angiogenesis in endometriosis[J].Reprod Sci,2009,16(2):140-146.
[16]Taylor RN,Yu J,Torres PB,et al.Mechanistic and therapeutic implications of angiogenesis in endometriosis[J].Reprod Sci,2009,16(2):140-146.
[17]Kuroda K,Kitade M,Kikuchi I,et al.Peritoneal vascular density assessment using narrow-band imaging and vascular analysis software,and cytokine analysis in women with and without endometriosis[J].J Minim Invasive Gynecol,2010,17(1):21-25.
[18]Bourlev V,Volkov N,Pavlovtch S,et al.The relationship between microvessel density,proliferative activity and expression of vascular endothclini growth factors and its receptors in eutopic endometrium and endometriotic ledons[J].Reproduc-tion,2006,32(1):501-509.
[19]陈景伟,杜惠兰,杨剑VEGF、HIF-1α在子宫内膜异位症中的表达及意义[J].第三军医大学学报,2010,32(1)：92-93.
[20]Khan KN,Nagasaki U.Peritoneal fluid and serum levels of hepatocyte growth factor may predict the activity of endometriosis[J].Acta Obstetricia Etgynecologica Scandinavica,2006,85(4):458.
[21]吴娟子,刘佳,朱桂金,等.肝细胞生长因子及其激活物在子宫内膜异位症的表达[J].中国妇幼保健,2008,23(28)：4033-4036.
[22]Park YH,Ryu HS,Choi DS.et al.Effects of hepatocyte growth factor on the expression of matrix metallo proteinase and their tissue inhibitors during the endomerial cancer invasion in a three-dimensional coculture[J].Int J Gynecol Cancer,2003,13(1):53-60.
[23]冷金花,郎景和,李华军,等.子宫内膜异位症非手术诊断方法探讨[J].现代妇产科进展.2007,16(11)：846-848,852.
[24]Liu HY,Zheng YH,Zhang JZ,et al.Establishment of endometriosis diagnostic model using plasma protein profiling[J]. Zhonghua Fu Chan Ke Za Zhi,2009,44(8):601-604.
[25]Jing J,Qiao Y,Suginami H,et al.Two novel serum biomarkers for endometriosis screened by surface enhanced laser desorption/ionization time of flight mass spectrometry and their change after laparoscopic removal of endometriosis[J]. Fertil Steril,2009,92(4):1221-1227.
[26]Pandis AK,Michal AL,Creigton SM,et al.Minimal access surgery in adolescent.gynaecology[J].BJOG,2009,116(2):214.
[27]Seracchioli R,Mabrouk M,Frasc C,et al.Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma:a randomized controlled trolled trial [J].Fertil Steril,2009,22(1):88.
[28]李桂玲,徐丛剑.青春期子宫内膜异位症的治疗策略[J].中国实用妇科与产科杂志,2010,26(7)：501-503.
[29]Bilotas M, Meresman G, Stella I, et al. Effect of aromatase inhibitors on ectopic endometrial growth and peritoneal environment in a mouse model of endometriosis[J].Fertil Steril,2010,93(8).
[30]Altintas D, Kokcu A, Tosun M. Comparison of the effects of cetrorelix, a GnRH antagonist, and leuprolide, a GnRH agonist, on experimental endometriosis[J]. J Obstet Gynaecol Res, 2008,34(6):1041-1019.
[31]王隆卉,蔡小荪.蔡小荪治疗子宫内膜异位症经验[J].世界中医药,2007,2(5)：282-283.
[32]程慧莲,李娟.加味四逆散治疗子宫内膜异位症引起的痛经临床疗效评价[J].辽宁中医杂志,2009,36(8)：1324-1326.
[33]汤艳秋,李娟.温阳化瘀法治疗子宫内膜异位症38例临床观察[J].江西中医药,2012,44(4)：343-344.
[34]潘芳.温通法治疗子宫内膜异位症及子宫肌腺症疼痛临床研究[J].山东中医药大学学报，,2011.35(2)：132-134.
[35]王蕊,刘勇,邢红梅.温经和营方治疗子宫内膜异位症相关不孕30例疗效观察[J].河北中医,2010,32(11)：1633-1634.
[36]魏绍斌,王妍,李白雪.内异康复片对子宫内膜异位症异位和在位内膜血管形成相关因子的实验研究[J].环球中医药，2011,37(4)：770-720.
[37]边文会,杜惠兰,陈惠娟.补肾温阳化瘀法治疗子宫内膜异位症的临床研究[J].中国全科医学,2009,12(4)：695-697.
[38]彭向军.子宫内膜异位症瘀血型证治分析[J].中国医药导报,2009,6(11)：142-143.
[39]具春花,陈玲.补肾活血方对内异症伴不孕患者子宫内膜的影响[J].辽宁中医杂志,2008,35(5)：722-724.
[40]李炜.中药保留灌肠治疗子宫内膜异位症的疗效观察[J].时珍国医国药,2009,20(5)：1258.
[41]周世谊.中药灌肠治疗子宫内膜异位症64例疗效观察[J].中国医药指南,2012,10(4)：224-225.
[42]魏绍斌,杨心弦,郭蓉晓,等.内异康复栓直肠给药对子宫内膜异位症模型大鼠血液流变的影响[J].中医药学刊,2006,24(2)：242-243.
[43]杨汉梅,杨忠华.侗药熏蒸治疗子宫内膜异位症[J].中国民族医药杂志,2009,15(7)：38.
[44]王中锐.灸盒灸配合生姜红糖酒治疗寒湿凝滞型原发性痛经56例[J].中国民间疗法,2011,19(7)：52-53.
[45]Marion M.Bradford[J]. Analytical Biochemistry,1976,72:248-254.
[46]Giovanni Candiano, Maurizio Bruschi, Luca Musante, et al., Blue silver:A very sensitive colloidal Coomassie G-250 staining for proteome analysis[J]. Electrophoresis 2004,25:1327-1333.
[47]Katayama H, Nagasu T, Oda Y, Improvement of in-gel digestion protocol for peptide mass fingerprinting by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry[J].Rapid Communications in Mass Spectrometry,2009,15:1416-1421.
[48]Coulombe PA,Wong P.Cytoplasmic intermediate filaments revealed as dynamic and multipurpose scaffolds[J].Nat Cell Biol,2004,6(8):699-706.
[49]Hu L,Lau SH,Tzang CH,et al.Association of Vimentin overexpression and hepatocellular carcinoma metastasis[J].Oncogene,2004,23(1):298-302.
[50]Zhao Yan,Yan Quanmei,Long Xing,et al.Vimentin affects the mobility and invasiveness of prostate cancer cells[J]. Cell Biochem Funct.2008,26(5):571-577.
[51]贾永喜,文艳君,魏于全.人波形蛋白重组质粒表达降低乳腺癌的增殖和侵袭[J].西部医学,2008,20(6)：1137-1140.
[52]Cristina Nodale,Michal Sheffer,Jasmine Jacob-Hirsch,et al.HIPK2 down regulates vimentin and inhibits breast cancer cell invasion[J].Cancer Biology & Therapy.2012,13(4)1-8.
[53]Guy Lahat,Quan-Sheng Zhu,Kai-Lieh Huang.et al.Vimentin Is a Novel Anti-Cancer Therapeutic Target;Insights from In Vitro and In Vivo Mice Xenograft Studies[J].PLoS ONE.2010,5(4):1-19.
[54]IN OK SONG,SUNG RAN HONG,YOUNGBUHM HUH,et al.Expression of Vimentin and Cytokeratin in Eutopic and Ectopic Endometrium of Women with Adenomyosis and Ovarian Endometrioma[J].American Journal of Reproductive Immunology.1998,40(1):26-31.
[55]Sachiko Matsuzaki,Claude Darcha.Epithelial to mesenchymal transition-like and mesenchymal to epithelial transition-like processes might be involved in the pathogenesis of pelvic endometriosis[J].Human Reproduction.2012,27(3):712-721.
[56]Nisolle M,Casanas Roux F,Donnez J,Expression of cytokeratin and vimentin in eutopic endometrium and endometriosis throughout the menstrual cycle:evaluation by a computerized method[J].Fertility and Sterility,1995,64(1):69-75.
[57]K.E.May, J. Villar, S. Kirtley,et al.Endometrial alterations in endometriosis:a systematic review of putative biomarkers[J].Human Reproduction Update,2011,17(5) 637-653.
[58]Yang Y,Liu Y,Yao X,et al.Annexin 1 released by necrotic human glioblastoma cells stimulates tumor cell growth throgh the formyl peptide receptor 1[J].Am J Pathol,2011,179(3):1504-1512.
[59]Lokman NA,Ween MP,Oehler MK,et al.The rule of annexin A2 in tumorigenesis and cancer progression[J].Cancer Microenviron,2011,4(2):199-208.
[60]Jung EJ,Moon HG,Park ST.et al.Decreased annexin A3 expression correlates wwith tumor progession in papillary thyroid cancer[J].Proteomics Clin Appl,2010,4(5):527-537.
[61]Monceaua V,Belikovaa Y,Kratassiouka G,et al.Externalization of endogenous annexin A5 participates in apoptosis of rat cardiomyocytes[J]. Cardiovascular Research,2004,64(3):496-506.
[62]Torosyan Y,Dobi A,Glasman M,et al.Role of multi-hnRNP nuclear complex in regulation of tumor suppressor ANX7 in prostate cancer cells[J].Oncogene,2010,29(17):2457-2466.
[63]Fang JY, Richardson B C. The MAPK signaling pathways and colorectal cancer[J]. Lancet Oncol,2005,6(5):322-327.
[64]李砍,高福禄,窦志杰.膜联蛋白A5过表达对宫颈癌细胞系SiHa细胞凋亡的影响[J].解剖学杂志,,2008,31(5)：668-673.
[65]李鹏鸽,杨艳丽,葛玉婷.膜联蛋白A2在肿瘤生长调节与细胞骨架活动中的作用[J].生理科学进展.2010,41(6)：457-460.
[66]A. Vodolazkaia,Y. El-Aalamat,D. Popovic,et al.Evaluation of a panel of 28 biomarkers for the non-invasive diagnosis of endometriosis[J].Human Reproduction,2012,27(9):2698-2711.
[67]Cleophas M. Kyama,Attila Mihalyi. Olivier Gevaert.et al.Evaluation of endometrial biomarkers for semi-invasive diagnosis of endometriosis[J]. Fertility and Sterility,2011,95(4):1338-1343.
[68]MH Wu,PC Chuang,YJ Lin.et al.Suppression of annexin A2 by prostaglandin E2 impairs phagocytic ability of peritoneal macrophages in women with endometriosis[J].Human Reproduction,2013,12.
[69]李妍,张淑兰,王丹波,等.膜联蛋白1在子宫内膜异位症患者在位内膜组织中的表达变化及其意义[J].中华妇产科杂志,2007,42(10)：705-706.
[70]FREGONESE L,STOLK J. HEREDITARY. Alpha-1-antitrypsin deficiency and its clinical consequences[M].Orphanet J Rare Dis,2008.
[71]Prins J,Meijden BB,Kraaijenhagen RJ,et al.Inherited Chronic Obstructive Pulmonary Disease:New Selective-Sequencing Workup for al-antitrypsin Deficiency Identifies 2 Previously Unidentified Null Alleles[J].Clinical Chemisto,2008,54(1):101-107.
[72]Dawkins PA,Dawkins CL,Wood AM,et al.Rate of progression of lung function impairment in α1-antitrypsin deficiency[J].Eur Respir J,2009,33(6):1338-1344.
[73]彭晶.α1-抗胰蛋白酶与老年冠心病的关系[J].医学信息,2011,24,(11)：311-312.
[74]王庆国,李玉强,滕晓梅,等.血清al-抗胰蛋白酶测定对原发性肝癌诊断及疗效观察的临床价值[J].国际检验医学杂志,2008,29(9)：841-842.
[75]赵慧辉,王伟.不稳定性心绞痛血瘀证的血浆蛋白组学研究[J].化学学报,2009,67(2)：167-173.
[76]陈新刚,舒建德,谢弘.人醛缩酶A单克隆抗体的制备及应用[J].中国免疫学杂志,1995,11(2)：88-91.
[77]范跃祖,伍福乐.醛缩酶同工酶A及其对原发性肝癌的临床意义[J].癌症,1989,8(1)：74-76.
[78]黄功华,梁景耀,陈碧.醛缩酶A可与人蛋白激酶CK2a’亚基发生特异相互作用[J].中国生物化学与分子生物学报.2004,20(5)：623-629.
[79]Sawa A,Khan AA.Hester LD,et al.Glyceraldehyde-3-phosphate dehydrogenase:Nuclear translocation participates in neuronal and nonneuronal cell death[J].Proc Natl Acad Sci,1997,94:11669-11674.
[80]Krynetski EY,Krynetskaia NF,Bianchi ME,et al.A nucleat protein complex containing high mobility group proteins B1 and B2,heat shock cognate protein 70,ERp60,and glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic reaponse to DNA modified by incorporation of anticancer nucleoside analogues[J].Cancer Res,2003,63:100-106.
[81]Azam S,Jouvet N,Jilani A,et al.Human glyceraldehyde-3-phosphate dehydrogenase plays a direst role in reactivating oxidized forms of the DNA repair enzyme APE1[J].Biol Chem,2008,283:30632-30641.
[82]Ishitani R,Tanaka M,Sunaga K,et al.Nuclear localization of over expressed glyceraldehyde-3-phosphate dehydrogenase in cultured cerebellar neurons under going apoptosis[J].Mol Pharmaco 1.1998,53:701-707.
[83]Q Huang, F Lan, Z Zheng, et al.Akt2 Kinase Suppresses Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH)-mediated Apoptosis in Ovarian Cancer Cells via Phosphorylating GAPDH at Threonine 237 and Decreasing Its Nuclear Translocation[J].The Journal of Biological chemistry,2011,286(49):42211-42220.
[84]T Matsuda, M Sakaguchi, S Tanaka,et al.Prolyl oligopeptidase is a glyceraldehyde-3-phosphate dehydrogenase-binding protein that regulates genotoxic stress-induced cell death[J].The International Journal of Biochemistry & Cell Biology,2013,45(4):850-857.
[85]J Huang, L Hao. N Xiong. X Cao,Involvement of glyceraldehyde-3-phosphate dehydrogenase in rotenone-induced cell apoptosis:Relevance to protein misfolding and aggregation[J].Brain Research,2009,1279(7):1-8.
[86]沈喜妹,杨立勇.3-磷酸甘油醛脱氢酶的多功能性及其在糖尿病的作用[J].福建医科大学学报,2007,41(5)：484-486.
[87]MA Rodriguez-Sastre,L Gonzalez-Maya,Del gadoR, et al.Abnormal distribution of E-cadherin and β-catenin in different histologic types of cancer of the uterine cervix[J]. Gynecologic Oncology,2005,97:330-336.
[88]J Reddy, P Chastagner, L Fiette.et al.IL-2-induced tumor necrosis factor (TNF)-β expression: further analysis in the IL-2 knockout model, and comparison with TNF-a, lymphotoxin-β, TNFR1 and TNFR2 modulation[J].International Immunology,2001,13(2):135-147.
[89]冯俊,李建军,应荣彪.微管蛋白在乳腺癌癌变不同阶段的表达及意义[J].中华临床医师杂志，2011,5(8)：2197-2200.
[90]应荣彪,冯俊,李建军.α、p-微管蛋白在乳腺癌变不同阶段的表达及意义[J].中国癌症杂志,2011，21(8)：595-598.
[91]卢红Beta-微管蛋白IEASODN对Ec9706／P-1细胞凋亡的影响[J].河南大学学报(医学版),2010，,29(3)：164-169.
[92]Mozzetti S, Ferlini C, Concolino P, et al. Class Ⅲ beta tubulin over expression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients[J]. Clin Cancer Res, 2005,11(1):298-305.
[93]吕玉宇,赵涌,巫静娴.宫颈永生化细胞和癌细胞的α、β、γ-微管蛋白比较分析[J].重庆医科大学学报,2008,33(12)1471-1474.
[94]贾艳滨,何红波,肖计划.阿尔茨海默病与血管性痴呆患者血浆p-微管蛋白和APP的变化[J].暨南大学学报(医学版),2008,29(2)：180-183.
[95]Ikeda S,Takabe K,Suzuki K.Expression of ERCC 1 and class Ⅲ beta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer[J]. Pathol Int,009,59(12):863-867.
[96]王辉,管姝轶,王追琴.β-微管蛋白在脑梗死患者血液中的表达及意义[J].现代实用医学,2011，23(5)：505-506.
[97]马民,辛晓燕,王滨,等.热休克蛋白在子宫内膜异位症中的表达及意义[J].细胞与分子免疫学杂志,2002,18(6)：571-574.
[98]Takashima S,Phosphorylation of myosin regulatory light chain by myosin light chain kinase,and muscle contraction[J].Circ J,2009,73(2):208-213.
[99]Himmel DM,Mui S,O'Neall-Hennessey E,et al.The on-of switch in regulated myosins: different triggers but related mechanisms[J]. J Mol Biol,2009,394(3):496-505.
[100]Huang C,Jacobson K,Schaller MD.MAP kinases and cell migration[J].Cell Sci,2004,117(20):4619-4628.
[101]辛华,郑雅娟,韩振国,等.肿瘤细胞向血管外游走过程中内皮细胞调控机制的研究[J].中国免疫学杂志.2004.20(11)：761-764.
[102]刘蕾,王伟,宋剑南,等.心肌缺血血瘀证小型猪模型差异蛋白质组学研究[J].中华中医药杂志,2009,24(6)：716-719.
[103]Ni M, Lee AS。ER chaperones in mammalian development and human diseases[J].FEBS Lett,2007,581(19):3641-3651.
[104]王艳林,曹春雨.钙网蛋白与凋亡细胞的清除[J].实用医学进修杂志,2007,35(3)：129-131.
[105]曹春雨,王艳林.钙网蛋白与凋亡细胞清除[J].生命的化学,2008,28(3)283-285.
[106]夏燕,王艳林.钙网蛋白的生物学特点及在肿瘤免疫治疗中的应用[J].山东医药,2012,52(23)：85-89.
[107]Chao MP, Jaiswal S, Weissman-Tsukamoto R, et al. Calreticulin is the dominant prophagocytic signal on multiple human cancers and is counterbalanced by CD47[J].Sci Transl Med,2010,2(63):1-9.
[108]JM Tarr, PJ Young, R Morse,et al.A Mechanism of Release of Calreticulin from Cells During Apoptosis[J].Journal of Molecular Biology,2010,401(5):799-812.
[109]Gardai SJ, Mc Phillips KA,Frasch SC,et al.Cell surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte[J].Cell,2005,123(2):321-334.
[110]Panaretakis T, Joza N, Modjtahedi N, et al. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death [J]. Cell Death Differ,2008,15(9):1499-1509.
[111]PJ Mosca, GP Robertson.Augmentation of tumor-specific immunity by upregulation of apoptotic melanoma cell calreticulin expression[J]. Cancer Biology & Therapy,2011(6):581-583.
[112]黄燕清,黄峥狲玲.腹腔液基质金属蛋白酶-1、-2、-3、-9与子宫内膜异位症的相关性[J].广东医学,2010,31(4)：433-435.
[113]孔令钧,李光华,李鲁扬.老年血瘀证与细胞黏附分子关系的探讨[J].山东中医药大学学报,2003,27(4)：274-276.
[114]张红栓,贾钰华,华何与.冠心病心绞痛痰浊证、血瘀证的尿液代谢组学研究[J].中国中医基础医学杂志,2010,16(2)：126-128.
[115]赵慧辉,王伟,郭淑贞.冠心病不稳定型心绞痛血瘀证的蛋白质组学[J].中国动脉硬化杂志,2008,16(7)：545-548.
[116]马晓娟,殷惠军,陈可冀.血瘀证与炎症相关性的研究进展[J].中国中西医结合杂志，2007.27(7)：669-672.
[117]徐洪云,曹玉民,李建霞.IL-6与子宫内膜异位症发病关系的研究[J].现代妇产科进展,2007,16(1)：57-59.
[118]HaradaT,KaponisA, IwabeT, et al.Apoptosis in human endometrium and endometriosis[J].Hum Reprod Update,2004,10(1):29-38.
[119]冯利霞,徐韶杰,孔翠花.子宫内膜异位症组织中survivin、PCNA的表达变化及临床意义[J].山东医药,2010，50(14)：77-78.
[120]Chae SJ, Kim H, Jee BC.et al.Tumor necrosis factor (TNF)-TNF receptor gene polymorphisms and their serum levels in Korean women with endometriosis[J].Am JReprod Immuno,l 2008,60 (5):432
[121]王锦华,邱如卿.崩漏肾虚血癖证与子宫内膜病理及细胞凋亡调控基因bcl-2、bax关系的研究[J].福建中医学院学报,2007,17(1)：3-6.
[122]胡学军,蔡光先,刘柏炎,等.蛋白质组学在中医“证”实质研究中的应用[J].中华中医药杂 志,2008,23(2)：87-91.
[123]丁海拔,盛梅笑.从组学探讨中医证候本质的研究概况[J].现代中西医结合杂志,2010,19(4)：502-504.
[124]倪红梅,徐燎宇.中医理论与现代医学的链接-基因组学[J].中国中医基础医学杂志,2002,8(12)：16.
[125]陈家旭.辨析证、病、体质关系,开展证候研究[J].中国中西医结合杂志,2002,22(6)：408.
[126]曹美群,吴正治,吴伟康,等.冠心病伴抑郁发作血瘀证／痰浊证的相关基因多态性研究[J].中国中医药科技,2010,17(5)：377-380.
[127]袁肇凯,王丽萍,黄献平,等.冠心病血瘀证遗传相关的差异基因筛选及其功能路径分析.中国中西医结合杂志,2012,32(10)：1313-1318.
[128]卢德赵,沃兴德.蛋白质组学技术在中医药研究中的应用[J].浙江中西医结合杂志,2007,17(4)：262-264.
[129]赵慧辉,陈建新,史琦,等.基于差异凝胶双向电泳技术的冠心病不稳定性心绞痛血瘀证患者血浆差异蛋白特征研究[J].中国中西医结合杂志,2010,30(5)：488-492.
[130]赵慧辉,王伟,王硕仁,等.冠心病心绞痛血瘀证的血浆双向电泳-质谱研究[J].中华中医药学刊,2008,26(4)：724-726.
[131]苗兰,潘映红,任建勋,等.血府逐瘀汤对气滞血瘀证大鼠血清蛋白质组表达的影响[J].中国实验方剂学杂志,2008,14(4)：24-28.
[132]李林,王建农,任建勋,等.气虚血瘀证大鼠尿液的核磁共振谱代谢组学[J].科学通报,2007,52(15)：1758-1762.
[133]张红栓,贾钰华,华何与,等.冠心病心绞痛痰浊证、血瘀证的尿液代谢组学研究[J].中国中医基础医学杂志,2010,16(2)：126-128.
[134]华何与,贾钰华,张红栓,等.冠心病心绞痛三种血瘀证的血浆代谢组学研究.热带医学杂志[J].2010,10(3)：258-260.
[1]朱明丹,杜武勋,姜民.中医证候与基因、蛋白质、代谢组学研究思路探讨[J].中国中医基础医学杂志.2010,16(I)：69-7I.
[2]潘志强,方肇勤.中医证候本质研究及引入系统生物学技术新趋势[J].中国中医药信息杂志,2009,16(1)：104-107.
[3]王米渠.中医遗传学[M].西宁：青海人民出版社,1997.245-291.
[4]王忠,王阶,王永炎.后基因维时代中医证候组学研究的思路[J].中国中西医结合杂志,2001,21(8)：621-623.
[5]王永炎,张启明,张志斌.证候要素及其靶位的提取[J].山东中医药大学学报,2006,30(1)：627.
[6]罗和古,陈家旭.代谢组学技术与中医证候的研究[J].中国中医药信息杂志,2007,14(5)：3-5.
[7]申维玺.论中医“证本质”的科学内涵[J].中国中医基础医学杂志,2001,7(6)：10-14.
[8]宋庆桥,胡元会,商秀洋,等.冠心病稳定型心绞痛血瘀证患者tPAl-1、sICAM-1及MMP-9的表达变化[J].中国中医急症,2011,20(9)：1377-1380.
[9]林钐,邓跃毅.慢性肾脏病各期ET、TXA2、PGI2的临床观察及与血瘀证关系的探讨[J].中国中西医结合肾病杂志，.2012,13(7)：615-617.
[10]张勤华,齐聪,黄宗瀚.气虚血瘀证卵巢癌大鼠的预后及其与肿瘤新生血管形成的相关性[J].上海中医药杂志,2007,41(6)：73-75.
[11]Wasinger VC,Cordwell SJ,Cerpa-Polja kA,et al.Progress with gene-product mapping of the Mollicutm:Mycoplasma genitalium[J].Electrophoresis,1995,16(7):1090-1094.
[12]卢德赵,沃兴德.蛋白质组学技术在中医药研究中的应用[J].浙江中西医结合杂志,2007,17(4)：262-264.
[13]赵慧辉,王伟.不稳定性心绞痛血瘀证的血浆蛋白组学研究∽.化学学报,2009,67(2)：167-173.
[14]赵慧辉,王伟,王硕仁,等.冠心病心绞痛血瘀证的血浆双向电泳-质谱研究[J].中华中医药学刊,2008,26(4)：724-726.
[15]赵慧辉,王伟,郭淑贞.冠心病不稳定型心绞痛血瘀证的蛋白质组学[J].中国动脉硬化杂志,2008,16(7)：545-548.
[16]赵慧辉,陈建新,史琦.等.基于差异凝胶双向电泳技术的冠心病不稳定性心绞痛血瘀证患者血浆差异蛋白特征研究叨.中国中西医结合杂志.2010,30(5)：488-492.
[17]刘涛,徐秋玲,王伟,等.气虚血瘀证大鼠模型缺血心肌蛋白质组学研究[J].江苏中医药,2010,42(7)：67-69.
[18]苗兰,刘建勋,任建勋,等.气虚血瘀证模型大鼠血清蛋白质组学初步研究叨.中国实验方剂学杂志,2009,15(9)：42-46.
[19]刘蕾,王伟,宋剑南,等.心肌缺血血瘀证小型猪模型差异蛋白质组学研究[J].中华中医药杂志,2009,24(6)：716-719.
[20]苗兰,潘映红.任建勋,等.血府逐瘀汤对气滞血瘀证大鼠血清蛋白质组表达的影响[J].中国实验方剂学杂志,2008,14(4)：24-28.
[21]华允芬,明震寰,张铭.药物基因组学研究进展[J].药学学报,2002,37(8)：668-672.
[22]倪红梅,徐燎宇.中医理论与现代医学的链接-基因组学[J].中国中医基础医学杂志.,2002,8(12)：16.
[23]陈家旭.辨析证、病、体质关系,开展证候研究[J].中国中西医结合杂志,2002,22(6)：408.
[24]马晓娟,殷惠军,陈可冀.血瘀证患者差异基因表达谱研究[J].中西医结合学报,2008,6(4)：355-360.
[25]曹美群,吴正治,吴伟康,等.冠心病伴抑郁发作血瘀证／痰浊证的相关基因多态性研究[J].中国中医药科技，2010,17(5)：377-380.
[26]袁肇凯,王丽萍,黄献平,等.冠心病血瘀证遗传相关的差异基因筛选及其功能路径分析[J].中国中西医结合杂志,2012,32(10)：1313-1318.
[27]骆杰伟,陈慧,吴小盈,等.去甲肾上腺素转运体基因启动子多态性及单倍体型与高血压病血瘀证的相关性研究[J].中国中西医结合杂志,2010,30(5)：458.-462.
[28]李林,王建农,任建勋,等.气虚血瘀证大鼠尿液的核磁共振谱代谢组学[J].科学通报，2007,52(15)：1758-1762.
[29]张红栓,贾钰华,华何与,等.冠心病心绞痛痰浊证、血瘀证的尿液代谢组学研究[J].中国中医基础医学杂志,2010,16(2)：126-128.
[30]华何与,贾钰华,张红栓,等.冠心病心绞痛三种血瘀证的血浆代谢组学研究[J].热带医学杂志,2010,10(3)：258-260.
[31]Wang Y,Guo SZ,Chen JX,et al. Analysis of plasma meta-bonomics of mini-swines with qi deficiency and blood stasis syndrome due to chronic myocardial ischemia[J].Zhong Xi Yi Jie He Xue Bao,2011,9(2):158-164.
[32]刘杰文,齐淑玲.血赛证实质和活血化赛药物作用机理的研究[J].中医药通报,2003,2(1)：2-9.
[33]常风云,常庚,申晓光，等.补阳还五汤合二甲双胍对2型糖尿病气虚血瘀证大鼠模型肾脏ICAM-1表达的影响[J].中成药,2010,32(6)：921-924.
[34]周玲,朱微微,罗云,等.祛瘀合剂对血瘀证大鼠血液流变学的影响[J].湖北中医学院学报,2009,11(6)：18-20.
[35]郭少贤,刘永惠,常靖,等.麝香酮干预血瘀证乳腺癌组织血管生成相关因子表达研究[J].河北中医药学报,201],26(2)：40.-41.
[36]李鑫辉,黄政德,田雪飞,等.益气活血法对血瘀证兔缺血再灌注心肌eNOS蛋白表达的影响[J].中国中医急症,2010,19(6)：993-995.
[37]张文宏,查良伦.血瘀证动物模型制作的回顾与展望[J].中国中西医结合杂志,1996,16(3)：184-185.
[38]任宏义,任周新.“气滞血瘀”证动物模型的建立[J].北京实验动物科学与管理,1994,11(3)：29-31.
[39]王学江,丰平.寒凝血瘀活动动物模型的实验研究[J].北京中医,2000,19(5)：52-53.
[40]王殿俊,刘小浩,金辉,等.热毒血瘀证动物模型的研制[J].南京中医学院学报,1992,8(1)：18-19.
[41]娄金丽,张允岭,郑宏,等.气虚血瘀证动物模型研究的思路与方法[J].北京中医药大学学报,2006,29(2)：87-90.
[42]郭移海,黄韧,连至诚,等.中医实验动物学[M].广州：暨南大学出版社,1999.175-178.
[43]任建勋,林成仁,王敏,等.多因素整合建立气滞血瘀证动物模型研究[J].中药药理与临床,2007,23(5)：210-211.
[44]任建勋,林成仁,刘建,等.多因素复合刺激诱导建立大鼠气虚血瘀证动物模型的探索性研究[J].中国中医药杂志,2011,36(1)：72-76.
[45]张斌,王中华,王江蓉,等.血瘀型肝纤维化大鼠模型的建立与评价[J].中国中医基础医学杂志,2006,12(11)：836-838.
[46]王硕仁,赵明镜,王振涛,等.建立心肌梗死气虚血液和心阳虚血瘀证病症动物模型的研究[J].中国中西医结合杂志,2008,28(3)：245-254.
[47]王晓东,李莉,张婷婷,等.恶露不尽血瘀证型动物模型建立及评价标准和作用机制研究[J].中国中医基础医学杂志,2011,17(11)：1200-1203.
[2]姚瑶珊,陈忠东.子宫内膜异位症发病机制的研究进展[J].中南医学科学杂志,2012,40(4)：413-415.
[3]Wasinger VC,Cordwell SJ,Cerpa-Polja kA,et al.Progress with gene-product mapping of the Mollicutm:Mycoplasma genitalium[J].Electrophoresis,1995,16(7):] 090-1094.
[4]卢德赵,沃兴德.蛋白质组学技术在中医药研究中的应用[J].浙江中西医结合杂志,2007,17(4)：262-264.
[5]朱明丹,杜武勋,姜民.中医证候与基因、蛋白质、代谢组学研究思路探讨[J].中国中医基础医学杂志,2010,16(1)：69-71.
[6]裘吉生主编,珍本医书集成·方书类(甲)[M].上海.上海科学技术出版社,1985：81.
[7]王东梅.“逆经痛”析[J].山东中医药大学学报.2000,(24)3：181-183.
[8]司徒仪主编,子宫内膜异位症中西医结合治疗[M].人民卫生出版社,2006年第1版：4.
[9]曹泽毅,主编.中华妇产科学[M],人民卫生出版社,2008年第二版：1486.
[10]郎景和.子宫内膜异位疟研究新理程[J].中华妇产科杂志，,2005,40(1)：3-4.
[11]郎景和.子宫内膜内膜异位症研究的任务与展望[J].中华妇产科杂志,2006,41(5)：289-290.
[12]宗利丽,李亚里,汪龙霞.子宫内膜异位症猕猴动物模型的建立[J].第一军医大学学报.，2003,，23(10)：1006-1009.
[13]黄燕清,黄峥狲玲,等.腹腔液基质金属蛋白酶-1、-2、-3、-9与子宫内膜异位症的相关性[J].广东医学,2010.31(4)：433-435.
[14]徐蕾,张向宁.内异症患者异位、在位子宫内膜中HGF、MMP-2、MMP-9的表达变化及意义[J].山东医药,2010,50：86-87.
[15]Taylor RN,Yu J.Torees PB,et al.Mechanistic and therapeutic implications of angiogenesis in endometriosis[J].Reprod Sci,2009,16(2):140-146.
[16]Taylor RN,Yu J,Torres PB,et al.Mechanistic and therapeutic implications of angiogenesis in endometriosis[J].Reprod Sci,2009,16(2):140-146.
[17]Kuroda K,Kitade M,Kikuchi I,et al.Peritoneal vascular density assessment using narrow-band imaging and vascular analysis software,and cytokine analysis in women with and without endometriosis[J].J Minim Invasive Gynecol,2010,17(1):21-25.
[18]Bourlev V,Volkov N,Pavlovtch S,et al.The relationship between microvessel density,proliferative activity and expression of vascular endothclini growth factors and its receptors in eutopic endometrium and endometriotic ledons[J].Reproduc-tion,2006,32(1):501-509.
[19]陈景伟,杜惠兰,杨剑VEGF、HIF-1α在子宫内膜异位症中的表达及意义[J].第三军医大学学报,2010,32(1)：92-93.
[20]Khan KN,Nagasaki U.Peritoneal fluid and serum levels of hepatocyte growth factor may predict the activity of endometriosis[J].Acta Obstetricia Etgynecologica Scandinavica,2006,85(4):458.
[21]吴娟子,刘佳,朱桂金,等.肝细胞生长因子及其激活物在子宫内膜异位症的表达[J].中国妇幼保健,2008,23(28)：4033-4036.
[22]Park YH,Ryu HS,Choi DS.et al.Effects of hepatocyte growth factor on the expression of matrix metallo proteinase and their tissue inhibitors during the endomerial cancer invasion in a three-dimensional coculture[J].Int J Gynecol Cancer,2003,13(1):53-60.
[23]冷金花,郎景和,李华军,等.子宫内膜异位症非手术诊断方法探讨[J].现代妇产科进展.2007,16(11)：846-848,852.
[24]Liu HY,Zheng YH,Zhang JZ,et al.Establishment of endometriosis diagnostic model using plasma protein profiling[J]. Zhonghua Fu Chan Ke Za Zhi,2009,44(8):601-604.
[25]Jing J,Qiao Y,Suginami H,et al.Two novel serum biomarkers for endometriosis screened by surface enhanced laser desorption/ionization time of flight mass spectrometry and their change after laparoscopic removal of endometriosis[J]. Fertil Steril,2009,92(4):1221-1227.
[26]Pandis AK,Michal AL,Creigton SM,et al.Minimal access surgery in adolescent.gynaecology[J].BJOG,2009,116(2):214.
[27]Seracchioli R,Mabrouk M,Frasc C,et al.Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma:a randomized controlled trolled trial [J].Fertil Steril,2009,22(1):88.
[28]李桂玲,徐丛剑.青春期子宫内膜异位症的治疗策略[J].中国实用妇科与产科杂志,2010,26(7)：501-503.
[29]Bilotas M, Meresman G, Stella I, et al. Effect of aromatase inhibitors on ectopic endometrial growth and peritoneal environment in a mouse model of endometriosis[J].Fertil Steril,2010,93(8).
[30]Altintas D, Kokcu A, Tosun M. Comparison of the effects of cetrorelix, a GnRH antagonist, and leuprolide, a GnRH agonist, on experimental endometriosis[J]. J Obstet Gynaecol Res, 2008,34(6):1041-1019.
[31]王隆卉,蔡小荪.蔡小荪治疗子宫内膜异位症经验[J].世界中医药,2007,2(5)：282-283.
[32]程慧莲,李娟.加味四逆散治疗子宫内膜异位症引起的痛经临床疗效评价[J].辽宁中医杂志,2009,36(8)：1324-1326.
[33]汤艳秋,李娟.温阳化瘀法治疗子宫内膜异位症38例临床观察[J].江西中医药,2012,44(4)：343-344.
[34]潘芳.温通法治疗子宫内膜异位症及子宫肌腺症疼痛临床研究[J].山东中医药大学学报，,2011.35(2)：132-134.
[35]王蕊,刘勇,邢红梅.温经和营方治疗子宫内膜异位症相关不孕30例疗效观察[J].河北中医,2010,32(11)：1633-1634.
[36]魏绍斌,王妍,李白雪.内异康复片对子宫内膜异位症异位和在位内膜血管形成相关因子的实验研究[J].环球中医药，2011,37(4)：770-720.
[37]边文会,杜惠兰,陈惠娟.补肾温阳化瘀法治疗子宫内膜异位症的临床研究[J].中国全科医学,2009,12(4)：695-697.
[38]彭向军.子宫内膜异位症瘀血型证治分析[J].中国医药导报,2009,6(11)：142-143.
[39]具春花,陈玲.补肾活血方对内异症伴不孕患者子宫内膜的影响[J].辽宁中医杂志,2008,35(5)：722-724.
[40]李炜.中药保留灌肠治疗子宫内膜异位症的疗效观察[J].时珍国医国药,2009,20(5)：1258.
[41]周世谊.中药灌肠治疗子宫内膜异位症64例疗效观察[J].中国医药指南,2012,10(4)：224-225.
[42]魏绍斌,杨心弦,郭蓉晓,等.内异康复栓直肠给药对子宫内膜异位症模型大鼠血液流变的影响[J].中医药学刊,2006,24(2)：242-243.
[43]杨汉梅,杨忠华.侗药熏蒸治疗子宫内膜异位症[J].中国民族医药杂志,2009,15(7)：38.
[44]王中锐.灸盒灸配合生姜红糖酒治疗寒湿凝滞型原发性痛经56例[J].中国民间疗法,2011,19(7)：52-53.
[45]Marion M.Bradford[J]. Analytical Biochemistry,1976,72:248-254.
[46]Giovanni Candiano, Maurizio Bruschi, Luca Musante, et al., Blue silver:A very sensitive colloidal Coomassie G-250 staining for proteome analysis[J]. Electrophoresis 2004,25:1327-1333.
[47]Katayama H, Nagasu T, Oda Y, Improvement of in-gel digestion protocol for peptide mass fingerprinting by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry[J].Rapid Communications in Mass Spectrometry,2009,15:1416-1421.
[48]Coulombe PA,Wong P.Cytoplasmic intermediate filaments revealed as dynamic and multipurpose scaffolds[J].Nat Cell Biol,2004,6(8):699-706.
[49]Hu L,Lau SH,Tzang CH,et al.Association of Vimentin overexpression and hepatocellular carcinoma metastasis[J].Oncogene,2004,23(1):298-302.
[50]Zhao Yan,Yan Quanmei,Long Xing,et al.Vimentin affects the mobility and invasiveness of prostate cancer cells[J]. Cell Biochem Funct.2008,26(5):571-577.
[51]贾永喜,文艳君,魏于全.人波形蛋白重组质粒表达降低乳腺癌的增殖和侵袭[J].西部医学,2008,20(6)：1137-1140.
[52]Cristina Nodale,Michal Sheffer,Jasmine Jacob-Hirsch,et al.HIPK2 down regulates vimentin and inhibits breast cancer cell invasion[J].Cancer Biology & Therapy.2012,13(4)1-8.
[53]Guy Lahat,Quan-Sheng Zhu,Kai-Lieh Huang.et al.Vimentin Is a Novel Anti-Cancer Therapeutic Target;Insights from In Vitro and In Vivo Mice Xenograft Studies[J].PLoS ONE.2010,5(4):1-19.
[54]IN OK SONG,SUNG RAN HONG,YOUNGBUHM HUH,et al.Expression of Vimentin and Cytokeratin in Eutopic and Ectopic Endometrium of Women with Adenomyosis and Ovarian Endometrioma[J].American Journal of Reproductive Immunology.1998,40(1):26-31.
[55]Sachiko Matsuzaki,Claude Darcha.Epithelial to mesenchymal transition-like and mesenchymal to epithelial transition-like processes might be involved in the pathogenesis of pelvic endometriosis[J].Human Reproduction.2012,27(3):712-721.
[56]Nisolle M,Casanas Roux F,Donnez J,Expression of cytokeratin and vimentin in eutopic endometrium and endometriosis throughout the menstrual cycle:evaluation by a computerized method[J].Fertility and Sterility,1995,64(1):69-75.
[57]K.E.May, J. Villar, S. Kirtley,et al.Endometrial alterations in endometriosis:a systematic review of putative biomarkers[J].Human Reproduction Update,2011,17(5) 637-653.
[58]Yang Y,Liu Y,Yao X,et al.Annexin 1 released by necrotic human glioblastoma cells stimulates tumor cell growth throgh the formyl peptide receptor 1[J].Am J Pathol,2011,179(3):1504-1512.
[59]Lokman NA,Ween MP,Oehler MK,et al.The rule of annexin A2 in tumorigenesis and cancer progression[J].Cancer Microenviron,2011,4(2):199-208.
[60]Jung EJ,Moon HG,Park ST.et al.Decreased annexin A3 expression correlates wwith tumor progession in papillary thyroid cancer[J].Proteomics Clin Appl,2010,4(5):527-537.
[61]Monceaua V,Belikovaa Y,Kratassiouka G,et al.Externalization of endogenous annexin A5 participates in apoptosis of rat cardiomyocytes[J]. Cardiovascular Research,2004,64(3):496-506.
[62]Torosyan Y,Dobi A,Glasman M,et al.Role of multi-hnRNP nuclear complex in regulation of tumor suppressor ANX7 in prostate cancer cells[J].Oncogene,2010,29(17):2457-2466.
[63]Fang JY, Richardson B C. The MAPK signaling pathways and colorectal cancer[J]. Lancet Oncol,2005,6(5):322-327.
[64]李砍,高福禄,窦志杰.膜联蛋白A5过表达对宫颈癌细胞系SiHa细胞凋亡的影响[J].解剖学杂志,,2008,31(5)：668-673.
[65]李鹏鸽,杨艳丽,葛玉婷.膜联蛋白A2在肿瘤生长调节与细胞骨架活动中的作用[J].生理科学进展.2010,41(6)：457-460.
[66]A. Vodolazkaia,Y. El-Aalamat,D. Popovic,et al.Evaluation of a panel of 28 biomarkers for the non-invasive diagnosis of endometriosis[J].Human Reproduction,2012,27(9):2698-2711.
[67]Cleophas M. Kyama,Attila Mihalyi. Olivier Gevaert.et al.Evaluation of endometrial biomarkers for semi-invasive diagnosis of endometriosis[J]. Fertility and Sterility,2011,95(4):1338-1343.
[68]MH Wu,PC Chuang,YJ Lin.et al.Suppression of annexin A2 by prostaglandin E2 impairs phagocytic ability of peritoneal macrophages in women with endometriosis[J].Human Reproduction,2013,12.
[69]李妍,张淑兰,王丹波,等.膜联蛋白1在子宫内膜异位症患者在位内膜组织中的表达变化及其意义[J].中华妇产科杂志,2007,42(10)：705-706.
[70]FREGONESE L,STOLK J. HEREDITARY. Alpha-1-antitrypsin deficiency and its clinical consequences[M].Orphanet J Rare Dis,2008.
[71]Prins J,Meijden BB,Kraaijenhagen RJ,et al.Inherited Chronic Obstructive Pulmonary Disease:New Selective-Sequencing Workup for al-antitrypsin Deficiency Identifies 2 Previously Unidentified Null Alleles[J].Clinical Chemisto,2008,54(1):101-107.
[72]Dawkins PA,Dawkins CL,Wood AM,et al.Rate of progression of lung function impairment in α1-antitrypsin deficiency[J].Eur Respir J,2009,33(6):1338-1344.
[73]彭晶.α1-抗胰蛋白酶与老年冠心病的关系[J].医学信息,2011,24,(11)：311-312.
[74]王庆国,李玉强,滕晓梅,等.血清al-抗胰蛋白酶测定对原发性肝癌诊断及疗效观察的临床价值[J].国际检验医学杂志,2008,29(9)：841-842.
[75]赵慧辉,王伟.不稳定性心绞痛血瘀证的血浆蛋白组学研究[J].化学学报,2009,67(2)：167-173.
[76]陈新刚,舒建德,谢弘.人醛缩酶A单克隆抗体的制备及应用[J].中国免疫学杂志,1995,11(2)：88-91.
[77]范跃祖,伍福乐.醛缩酶同工酶A及其对原发性肝癌的临床意义[J].癌症,1989,8(1)：74-76.
[78]黄功华,梁景耀,陈碧.醛缩酶A可与人蛋白激酶CK2a’亚基发生特异相互作用[J].中国生物化学与分子生物学报.2004,20(5)：623-629.
[79]Sawa A,Khan AA.Hester LD,et al.Glyceraldehyde-3-phosphate dehydrogenase:Nuclear translocation participates in neuronal and nonneuronal cell death[J].Proc Natl Acad Sci,1997,94:11669-11674.
[80]Krynetski EY,Krynetskaia NF,Bianchi ME,et al.A nucleat protein complex containing high mobility group proteins B1 and B2,heat shock cognate protein 70,ERp60,and glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic reaponse to DNA modified by incorporation of anticancer nucleoside analogues[J].Cancer Res,2003,63:100-106.
[81]Azam S,Jouvet N,Jilani A,et al.Human glyceraldehyde-3-phosphate dehydrogenase plays a direst role in reactivating oxidized forms of the DNA repair enzyme APE1[J].Biol Chem,2008,283:30632-30641.
[82]Ishitani R,Tanaka M,Sunaga K,et al.Nuclear localization of over expressed glyceraldehyde-3-phosphate dehydrogenase in cultured cerebellar neurons under going apoptosis[J].Mol Pharmaco 1.1998,53:701-707.
[83]Q Huang, F Lan, Z Zheng, et al.Akt2 Kinase Suppresses Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH)-mediated Apoptosis in Ovarian Cancer Cells via Phosphorylating GAPDH at Threonine 237 and Decreasing Its Nuclear Translocation[J].The Journal of Biological chemistry,2011,286(49):42211-42220.
[84]T Matsuda, M Sakaguchi, S Tanaka,et al.Prolyl oligopeptidase is a glyceraldehyde-3-phosphate dehydrogenase-binding protein that regulates genotoxic stress-induced cell death[J].The International Journal of Biochemistry & Cell Biology,2013,45(4):850-857.
[85]J Huang, L Hao. N Xiong. X Cao,Involvement of glyceraldehyde-3-phosphate dehydrogenase in rotenone-induced cell apoptosis:Relevance to protein misfolding and aggregation[J].Brain Research,2009,1279(7):1-8.
[86]沈喜妹,杨立勇.3-磷酸甘油醛脱氢酶的多功能性及其在糖尿病的作用[J].福建医科大学学报,2007,41(5)：484-486.
[87]MA Rodriguez-Sastre,L Gonzalez-Maya,Del gadoR, et al.Abnormal distribution of E-cadherin and β-catenin in different histologic types of cancer of the uterine cervix[J]. Gynecologic Oncology,2005,97:330-336.
[88]J Reddy, P Chastagner, L Fiette.et al.IL-2-induced tumor necrosis factor (TNF)-β expression: further analysis in the IL-2 knockout model, and comparison with TNF-a, lymphotoxin-β, TNFR1 and TNFR2 modulation[J].International Immunology,2001,13(2):135-147.
[89]冯俊,李建军,应荣彪.微管蛋白在乳腺癌癌变不同阶段的表达及意义[J].中华临床医师杂志，2011,5(8)：2197-2200.
[90]应荣彪,冯俊,李建军.α、p-微管蛋白在乳腺癌变不同阶段的表达及意义[J].中国癌症杂志,2011，21(8)：595-598.
[91]卢红Beta-微管蛋白IEASODN对Ec9706／P-1细胞凋亡的影响[J].河南大学学报(医学版),2010，,29(3)：164-169.
[92]Mozzetti S, Ferlini C, Concolino P, et al. Class Ⅲ beta tubulin over expression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients[J]. Clin Cancer Res, 2005,11(1):298-305.
[93]吕玉宇,赵涌,巫静娴.宫颈永生化细胞和癌细胞的α、β、γ-微管蛋白比较分析[J].重庆医科大学学报,2008,33(12)1471-1474.
[94]贾艳滨,何红波,肖计划.阿尔茨海默病与血管性痴呆患者血浆p-微管蛋白和APP的变化[J].暨南大学学报(医学版),2008,29(2)：180-183.
[95]Ikeda S,Takabe K,Suzuki K.Expression of ERCC 1 and class Ⅲ beta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer[J]. Pathol Int,009,59(12):863-867.
[96]王辉,管姝轶,王追琴.β-微管蛋白在脑梗死患者血液中的表达及意义[J].现代实用医学,2011，23(5)：505-506.
[97]马民,辛晓燕,王滨,等.热休克蛋白在子宫内膜异位症中的表达及意义[J].细胞与分子免疫学杂志,2002,18(6)：571-574.
[98]Takashima S,Phosphorylation of myosin regulatory light chain by myosin light chain kinase,and muscle contraction[J].Circ J,2009,73(2):208-213.
[99]Himmel DM,Mui S,O'Neall-Hennessey E,et al.The on-of switch in regulated myosins: different triggers but related mechanisms[J]. J Mol Biol,2009,394(3):496-505.
[100]Huang C,Jacobson K,Schaller MD.MAP kinases and cell migration[J].Cell Sci,2004,117(20):4619-4628.
[101]辛华,郑雅娟,韩振国,等.肿瘤细胞向血管外游走过程中内皮细胞调控机制的研究[J].中国免疫学杂志.2004.20(11)：761-764.
[102]刘蕾,王伟,宋剑南,等.心肌缺血血瘀证小型猪模型差异蛋白质组学研究[J].中华中医药杂志,2009,24(6)：716-719.
[103]Ni M, Lee AS。ER chaperones in mammalian development and human diseases[J].FEBS Lett,2007,581(19):3641-3651.
[104]王艳林,曹春雨.钙网蛋白与凋亡细胞的清除[J].实用医学进修杂志,2007,35(3)：129-131.
[105]曹春雨,王艳林.钙网蛋白与凋亡细胞清除[J].生命的化学,2008,28(3)283-285.
[106]夏燕,王艳林.钙网蛋白的生物学特点及在肿瘤免疫治疗中的应用[J].山东医药,2012,52(23)：85-89.
[107]Chao MP, Jaiswal S, Weissman-Tsukamoto R, et al. Calreticulin is the dominant prophagocytic signal on multiple human cancers and is counterbalanced by CD47[J].Sci Transl Med,2010,2(63):1-9.
[108]JM Tarr, PJ Young, R Morse,et al.A Mechanism of Release of Calreticulin from Cells During Apoptosis[J].Journal of Molecular Biology,2010,401(5):799-812.
[109]Gardai SJ, Mc Phillips KA,Frasch SC,et al.Cell surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte[J].Cell,2005,123(2):321-334.
[110]Panaretakis T, Joza N, Modjtahedi N, et al. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death [J]. Cell Death Differ,2008,15(9):1499-1509.
[111]PJ Mosca, GP Robertson.Augmentation of tumor-specific immunity by upregulation of apoptotic melanoma cell calreticulin expression[J]. Cancer Biology & Therapy,2011(6):581-583.
[112]黄燕清,黄峥狲玲.腹腔液基质金属蛋白酶-1、-2、-3、-9与子宫内膜异位症的相关性[J].广东医学,2010,31(4)：433-435.
[113]孔令钧,李光华,李鲁扬.老年血瘀证与细胞黏附分子关系的探讨[J].山东中医药大学学报,2003,27(4)：274-276.
[114]张红栓,贾钰华,华何与.冠心病心绞痛痰浊证、血瘀证的尿液代谢组学研究[J].中国中医基础医学杂志,2010,16(2)：126-128.
[115]赵慧辉,王伟,郭淑贞.冠心病不稳定型心绞痛血瘀证的蛋白质组学[J].中国动脉硬化杂志,2008,16(7)：545-548.
[116]马晓娟,殷惠军,陈可冀.血瘀证与炎症相关性的研究进展[J].中国中西医结合杂志，2007.27(7)：669-672.
[117]徐洪云,曹玉民,李建霞.IL-6与子宫内膜异位症发病关系的研究[J].现代妇产科进展,2007,16(1)：57-59.
[118]HaradaT,KaponisA, IwabeT, et al.Apoptosis in human endometrium and endometriosis[J].Hum Reprod Update,2004,10(1):29-38.
[119]冯利霞,徐韶杰,孔翠花.子宫内膜异位症组织中survivin、PCNA的表达变化及临床意义[J].山东医药,2010，50(14)：77-78.
[120]Chae SJ, Kim H, Jee BC.et al.Tumor necrosis factor (TNF)-TNF receptor gene polymorphisms and their serum levels in Korean women with endometriosis[J].Am JReprod Immuno,l 2008,60 (5):432
[121]王锦华,邱如卿.崩漏肾虚血癖证与子宫内膜病理及细胞凋亡调控基因bcl-2、bax关系的研究[J].福建中医学院学报,2007,17(1)：3-6.
[122]胡学军,蔡光先,刘柏炎,等.蛋白质组学在中医“证”实质研究中的应用[J].中华中医药杂 志,2008,23(2)：87-91.
[123]丁海拔,盛梅笑.从组学探讨中医证候本质的研究概况[J].现代中西医结合杂志,2010,19(4)：502-504.
[124]倪红梅,徐燎宇.中医理论与现代医学的链接-基因组学[J].中国中医基础医学杂志,2002,8(12)：16.
[125]陈家旭.辨析证、病、体质关系,开展证候研究[J].中国中西医结合杂志,2002,22(6)：408.
[126]曹美群,吴正治,吴伟康,等.冠心病伴抑郁发作血瘀证／痰浊证的相关基因多态性研究[J].中国中医药科技,2010,17(5)：377-380.
[127]袁肇凯,王丽萍,黄献平,等.冠心病血瘀证遗传相关的差异基因筛选及其功能路径分析.中国中西医结合杂志,2012,32(10)：1313-1318.
[128]卢德赵,沃兴德.蛋白质组学技术在中医药研究中的应用[J].浙江中西医结合杂志,2007,17(4)：262-264.
[129]赵慧辉,陈建新,史琦,等.基于差异凝胶双向电泳技术的冠心病不稳定性心绞痛血瘀证患者血浆差异蛋白特征研究[J].中国中西医结合杂志,2010,30(5)：488-492.
[130]赵慧辉,王伟,王硕仁,等.冠心病心绞痛血瘀证的血浆双向电泳-质谱研究[J].中华中医药学刊,2008,26(4)：724-726.
[131]苗兰,潘映红,任建勋,等.血府逐瘀汤对气滞血瘀证大鼠血清蛋白质组表达的影响[J].中国实验方剂学杂志,2008,14(4)：24-28.
[132]李林,王建农,任建勋,等.气虚血瘀证大鼠尿液的核磁共振谱代谢组学[J].科学通报,2007,52(15)：1758-1762.
[133]张红栓,贾钰华,华何与,等.冠心病心绞痛痰浊证、血瘀证的尿液代谢组学研究[J].中国中医基础医学杂志,2010,16(2)：126-128.
[134]华何与,贾钰华,张红栓,等.冠心病心绞痛三种血瘀证的血浆代谢组学研究.热带医学杂志[J].2010,10(3)：258-260.
[1]朱明丹,杜武勋,姜民.中医证候与基因、蛋白质、代谢组学研究思路探讨[J].中国中医基础医学杂志.2010,16(I)：69-7I.
[2]潘志强,方肇勤.中医证候本质研究及引入系统生物学技术新趋势[J].中国中医药信息杂志,2009,16(1)：104-107.
[3]王米渠.中医遗传学[M].西宁：青海人民出版社,1997.245-291.
[4]王忠,王阶,王永炎.后基因维时代中医证候组学研究的思路[J].中国中西医结合杂志,2001,21(8)：621-623.
[5]王永炎,张启明,张志斌.证候要素及其靶位的提取[J].山东中医药大学学报,2006,30(1)：627.
[6]罗和古,陈家旭.代谢组学技术与中医证候的研究[J].中国中医药信息杂志,2007,14(5)：3-5.
[7]申维玺.论中医“证本质”的科学内涵[J].中国中医基础医学杂志,2001,7(6)：10-14.
[8]宋庆桥,胡元会,商秀洋,等.冠心病稳定型心绞痛血瘀证患者tPAl-1、sICAM-1及MMP-9的表达变化[J].中国中医急症,2011,20(9)：1377-1380.
[9]林钐,邓跃毅.慢性肾脏病各期ET、TXA2、PGI2的临床观察及与血瘀证关系的探讨[J].中国中西医结合肾病杂志，.2012,13(7)：615-617.
[10]张勤华,齐聪,黄宗瀚.气虚血瘀证卵巢癌大鼠的预后及其与肿瘤新生血管形成的相关性[J].上海中医药杂志,2007,41(6)：73-75.
[11]Wasinger VC,Cordwell SJ,Cerpa-Polja kA,et al.Progress with gene-product mapping of the Mollicutm:Mycoplasma genitalium[J].Electrophoresis,1995,16(7):1090-1094.
[12]卢德赵,沃兴德.蛋白质组学技术在中医药研究中的应用[J].浙江中西医结合杂志,2007,17(4)：262-264.
[13]赵慧辉,王伟.不稳定性心绞痛血瘀证的血浆蛋白组学研究∽.化学学报,2009,67(2)：167-173.
[14]赵慧辉,王伟,王硕仁,等.冠心病心绞痛血瘀证的血浆双向电泳-质谱研究[J].中华中医药学刊,2008,26(4)：724-726.
[15]赵慧辉,王伟,郭淑贞.冠心病不稳定型心绞痛血瘀证的蛋白质组学[J].中国动脉硬化杂志,2008,16(7)：545-548.
[16]赵慧辉,陈建新,史琦.等.基于差异凝胶双向电泳技术的冠心病不稳定性心绞痛血瘀证患者血浆差异蛋白特征研究叨.中国中西医结合杂志.2010,30(5)：488-492.
[17]刘涛,徐秋玲,王伟,等.气虚血瘀证大鼠模型缺血心肌蛋白质组学研究[J].江苏中医药,2010,42(7)：67-69.
[18]苗兰,刘建勋,任建勋,等.气虚血瘀证模型大鼠血清蛋白质组学初步研究叨.中国实验方剂学杂志,2009,15(9)：42-46.
[19]刘蕾,王伟,宋剑南,等.心肌缺血血瘀证小型猪模型差异蛋白质组学研究[J].中华中医药杂志,2009,24(6)：716-719.
[20]苗兰,潘映红.任建勋,等.血府逐瘀汤对气滞血瘀证大鼠血清蛋白质组表达的影响[J].中国实验方剂学杂志,2008,14(4)：24-28.
[21]华允芬,明震寰,张铭.药物基因组学研究进展[J].药学学报,2002,37(8)：668-672.
[22]倪红梅,徐燎宇.中医理论与现代医学的链接-基因组学[J].中国中医基础医学杂志.,2002,8(12)：16.
[23]陈家旭.辨析证、病、体质关系,开展证候研究[J].中国中西医结合杂志,2002,22(6)：408.
[24]马晓娟,殷惠军,陈可冀.血瘀证患者差异基因表达谱研究[J].中西医结合学报,2008,6(4)：355-360.
[25]曹美群,吴正治,吴伟康,等.冠心病伴抑郁发作血瘀证／痰浊证的相关基因多态性研究[J].中国中医药科技，2010,17(5)：377-380.
[26]袁肇凯,王丽萍,黄献平,等.冠心病血瘀证遗传相关的差异基因筛选及其功能路径分析[J].中国中西医结合杂志,2012,32(10)：1313-1318.
[27]骆杰伟,陈慧,吴小盈,等.去甲肾上腺素转运体基因启动子多态性及单倍体型与高血压病血瘀证的相关性研究[J].中国中西医结合杂志,2010,30(5)：458.-462.
[28]李林,王建农,任建勋,等.气虚血瘀证大鼠尿液的核磁共振谱代谢组学[J].科学通报，2007,52(15)：1758-1762.
[29]张红栓,贾钰华,华何与,等.冠心病心绞痛痰浊证、血瘀证的尿液代谢组学研究[J].中国中医基础医学杂志,2010,16(2)：126-128.
[30]华何与,贾钰华,张红栓,等.冠心病心绞痛三种血瘀证的血浆代谢组学研究[J].热带医学杂志,2010,10(3)：258-260.
[31]Wang Y,Guo SZ,Chen JX,et al. Analysis of plasma meta-bonomics of mini-swines with qi deficiency and blood stasis syndrome due to chronic myocardial ischemia[J].Zhong Xi Yi Jie He Xue Bao,2011,9(2):158-164.
[32]刘杰文,齐淑玲.血赛证实质和活血化赛药物作用机理的研究[J].中医药通报,2003,2(1)：2-9.
[33]常风云,常庚,申晓光，等.补阳还五汤合二甲双胍对2型糖尿病气虚血瘀证大鼠模型肾脏ICAM-1表达的影响[J].中成药,2010,32(6)：921-924.
[34]周玲,朱微微,罗云,等.祛瘀合剂对血瘀证大鼠血液流变学的影响[J].湖北中医学院学报,2009,11(6)：18-20.
[35]郭少贤,刘永惠,常靖,等.麝香酮干预血瘀证乳腺癌组织血管生成相关因子表达研究[J].河北中医药学报,201],26(2)：40.-41.
[36]李鑫辉,黄政德,田雪飞,等.益气活血法对血瘀证兔缺血再灌注心肌eNOS蛋白表达的影响[J].中国中医急症,2010,19(6)：993-995.
[37]张文宏,查良伦.血瘀证动物模型制作的回顾与展望[J].中国中西医结合杂志,1996,16(3)：184-185.
[38]任宏义,任周新.“气滞血瘀”证动物模型的建立[J].北京实验动物科学与管理,1994,11(3)：29-31.
[39]王学江,丰平.寒凝血瘀活动动物模型的实验研究[J].北京中医,2000,19(5)：52-53.
[40]王殿俊,刘小浩,金辉,等.热毒血瘀证动物模型的研制[J].南京中医学院学报,1992,8(1)：18-19.
[41]娄金丽,张允岭,郑宏,等.气虚血瘀证动物模型研究的思路与方法[J].北京中医药大学学报,2006,29(2)：87-90.
[42]郭移海,黄韧,连至诚,等.中医实验动物学[M].广州：暨南大学出版社,1999.175-178.
[43]任建勋,林成仁,王敏,等.多因素整合建立气滞血瘀证动物模型研究[J].中药药理与临床,2007,23(5)：210-211.
[44]任建勋,林成仁,刘建,等.多因素复合刺激诱导建立大鼠气虚血瘀证动物模型的探索性研究[J].中国中医药杂志,2011,36(1)：72-76.
[45]张斌,王中华,王江蓉,等.血瘀型肝纤维化大鼠模型的建立与评价[J].中国中医基础医学杂志,2006,12(11)：836-838.
[46]王硕仁,赵明镜,王振涛,等.建立心肌梗死气虚血液和心阳虚血瘀证病症动物模型的研究[J].中国中西医结合杂志,2008,28(3)：245-254.
[47]王晓东,李莉,张婷婷,等.恶露不尽血瘀证型动物模型建立及评价标准和作用机制研究[J].中国中医基础医学杂志,2011,17(11)：1200-1203.